Hepatitis C Virus Risk Differs Among Hispanic Groups
The prevalence of hepatitis C virus varies significantly among different subtypes of Hispanics in the United States, a new study finds.
The prevalence of hepatitis C virus (HCV) varies significantly among different subtypes of Hispanics in the United States, a new study finds.
HCV rates among Hispanics have been reported to be similar to those of white Americans. However, these reports only distinguish rates for Mexican Americans and do not consider potential differences in prevalence among other groups of Hispanics who are grouped into the same category. To quantify these risk differences, the study, published online on January 13, 2014, in The Journal of Infectious Diseases, evaluated Hispanic participants in the National Health and Nutrition Examination Survey (NHANES) 2007-2010 and in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), conducted from 2008 through 2011.
Hispanic participants in the NHANES study were 63% Mexican, while the HCHS/SOL was more mixed, with Mexican, Cuban, Puerto Rican, Dominican, Central American, and South American participants. Overall, the prevalence of HCV antibodies was similar among the 2 study groups: 1.5% in NHANES and 2% in HCHS/SOL. However, HCV risk varied significantly between specific ethnicities. Only 0.4% of men from South America were infected with HCV compared with 11.6% of Puerto Rican men.
“These findings suggest that the HCV epidemic among US Hispanics/ Latinos is heterogeneous,” the authors of the study suggest.
Articles in this issue
over 11 years ago
Article
Combination Therapy, Early Treatment Improve Survival in Severe Pneumonia CasesNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025